Publication Details
Abstract
The review article explores the potential of population-based genetic testing (PBGT) for the precision prevention of women's cancers, focusing on breast, ovarian, and endometrial cancers. Current genetic testing strategies, primarily based on family history models, have significant limitations, leading to underutilization and missed opportunities for early cancer detection and prevention. PBGT offers a novel approach by enabling broader identification of cancer-susceptibility gene (CSG) carriers, facilitating targeted screening, and preventive interventions. The review addresses the psychological, economic, and ethical implications of PBGT, highlighting its feasibility, cost-effectiveness, and impact on cancer incidence reduction. Research findings suggest high acceptability and satisfaction with PBGT, especially in founder populations like the Ashkenazi-Jewish community, where unselected BRCA testing has shown to be feasible, reduce anxiety, and potentially save costs. However, the review underscores the need for further studies in diverse populations to address specific cultural concerns and optimize counseling and education strategies. The implications of PBGT extend beyond individual health benefits, providing opportunities for family planning and cascade testing among relatives, thus amplifying its preventive impact. The article concludes by advocating for the integration of PBGT into healthcare systems to enhance early detection and precision prevention of women's cancers.